Production Scanners

PRODUCTS

  • This is a test document. It has a lot of non-sense information, some may even call it bogus data. This is a test document. It has a lot of non-sense information, some may even call it bogus data. This is a test document. It has a lot of non-sense information, some may even call it bogus data.

  • Solutions for rapid response to vaccine development and manufacturing challenges

    Vaccine development trends emphasize the need for adaptability and accessible production facilities. Remote manufacturing tackles these challenges, facilitating decentralized vaccine production and rapid responses to health crises. Germfree, a leading cleanroom manufacturer, remains at the forefront of these trends by providing configurable solutions that satisfy regulatory requirements and end-user needs. By leveraging innovative remote manufacturing technologies, Germfree helps shape a more dynamic and efficient future for vaccine development and production.

  • EirGenix provides client-oriented contract development and manufacturing services for biologics, especially monoclonal antibodies and biosimilars. Combining the capabilities of EirGenix’s strategic partner, Formosa Laboratories, Inc, a high potency API manufacturer, we offer integrated services for Antibody Drug Conjugate (ADC) development and manufacturing.

  • Delivering on the promise of cell and gene therapy through Germfree products and services.

    Germfree Laboratories offer advanced modular and mobile facilities, equipment, and comprehensive services for cell therapy manufacturing. Acknowledging the complexity of personalized treatments, Germfree’s adaptable solutions optimize production processes, ensuring aseptic conditions, scalability, and compliance with regulatory standards. This enables efficient, high-quality cell therapy delivery to patients in need, supporting manufacturers in overcoming industry challenges.

  • Protein A chromatography resin with excellent capacity and alkaline stability for cost-efficient and extremely robust mAb capture.

WHITE PAPERS AND CASE STUDIES

NEWS